M A Bowen

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. ncbi Characterization of mouse ALCAM (CD166): the CD6-binding domain is conserved in different homologs and mediates cross-species binding
    M A Bowen
    Bristol Myers Squibb Pharmaceutical Research Institute, Seattle, WA 98121, USA
    Eur J Immunol 27:1469-78. 1997
  2. ncbi Recognition of diverse proteins by members of the immunoglobulin superfamily: delineation of the receptor binding site in the human CD6 ligand ALCAM
    J E Skonier
    Bristol Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121, USA
    Biochemistry 35:12287-91. 1996
  3. ncbi CD6-ligand interactions: a paradigm for SRCR domain function?
    A Aruffo
    Bristol Myers Squibb Pharmaceutical Research Institute, Seattle, WA 98121, USA
    Immunol Today 18:498-504. 1997
  4. ncbi Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand
    M A Bowen
    Bristol Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121, USA
    J Exp Med 181:2213-20. 1995
  5. ncbi Characterization of mouse CD6 with novel monoclonal antibodies which enhance the allogeneic mixed leukocyte reaction
    G C Starling
    Bristol Myers Squibb Pharmaceutical Research Institute, Seattle, WA 98121, USA
    Eur J Immunol 26:738-46. 1996
  6. ncbi The membrane-proximal scavenger receptor cysteine-rich domain of CD6 contains the activated leukocyte cell adhesion molecule binding site
    G S Whitney
    Bristol Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121, USA
    J Biol Chem 270:18187-90. 1995
  7. ncbi Structure and expression of murine CD30 and its role in cytokine production
    M A Bowen
    Bristol Myers Squibb Pharmaceutical Research Institute, Seattle, WA 98121, USA
    J Immunol 156:442-9. 1996
  8. ncbi Analysis of the tyrosine phosphorylation and calcium fluxing of human CD6 isoforms with different cytoplasmatic domains
    J Kobarg
    Bristol Myers Squibb Pharmaceutical Research Institute, Seattle, USA
    Eur J Immunol 27:2971-80. 1997
  9. ncbi Molecular model of the N-terminal receptor-binding domain of the human CD6 ligand ALCAM
    J Bajorath
    Bristol Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121, USA
    Protein Sci 4:1644-7. 1995
  10. ncbi Structure and chromosomal location of the human CD6 gene: detection of five human CD6 isoforms
    M A Bowen
    Bristol Myers Squibb Pharmaceutical Research Institute, Seattle, WA 98121, USA
    J Immunol 158:1149-56. 1997

Collaborators

Detail Information

Publications14

  1. ncbi Characterization of mouse ALCAM (CD166): the CD6-binding domain is conserved in different homologs and mediates cross-species binding
    M A Bowen
    Bristol Myers Squibb Pharmaceutical Research Institute, Seattle, WA 98121, USA
    Eur J Immunol 27:1469-78. 1997
    ..A rat mAb specific for mALCAM was produced and by two-color immunofluorescence studies was shown to bind to both activated CD4+ and CD8+ T cells...
  2. ncbi Recognition of diverse proteins by members of the immunoglobulin superfamily: delineation of the receptor binding site in the human CD6 ligand ALCAM
    J E Skonier
    Bristol Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121, USA
    Biochemistry 35:12287-91. 1996
    ..This provides a molecular rationale for the inability to obtain murine monoclonal antibodies against the receptor binding domain which block the CD6-ALCAM interaction...
  3. ncbi CD6-ligand interactions: a paradigm for SRCR domain function?
    A Aruffo
    Bristol Myers Squibb Pharmaceutical Research Institute, Seattle, WA 98121, USA
    Immunol Today 18:498-504. 1997
    ..Analysis of the CD6-ALCAM interaction may help to understand how other SRCR domains bind to their ligands...
  4. ncbi Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand
    M A Bowen
    Bristol Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121, USA
    J Exp Med 181:2213-20. 1995
    ....
  5. ncbi Characterization of mouse CD6 with novel monoclonal antibodies which enhance the allogeneic mixed leukocyte reaction
    G C Starling
    Bristol Myers Squibb Pharmaceutical Research Institute, Seattle, WA 98121, USA
    Eur J Immunol 26:738-46. 1996
    ..Anti-mCD6 mAb enhanced allogeneic mixed leukocyte reactions (MLR), indicating that CD6-ALCAM interactions may regulate the proliferative capacity of T cells...
  6. ncbi The membrane-proximal scavenger receptor cysteine-rich domain of CD6 contains the activated leukocyte cell adhesion molecule binding site
    G S Whitney
    Bristol Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121, USA
    J Biol Chem 270:18187-90. 1995
    ..These results demonstrate that the membrane-proximal SRCR domain of CD6 is necessary for CD6 binding to ALCAM and provide the first direct evidence for the interaction of an SRCR domain with a ligand...
  7. ncbi Structure and expression of murine CD30 and its role in cytokine production
    M A Bowen
    Bristol Myers Squibb Pharmaceutical Research Institute, Seattle, WA 98121, USA
    J Immunol 156:442-9. 1996
    ..These studies demonstrate that CD30 directs cytokine secretion and suggest that CD30 signaling may be pivotal in the pattern of cytokine production by T cells...
  8. ncbi Analysis of the tyrosine phosphorylation and calcium fluxing of human CD6 isoforms with different cytoplasmatic domains
    J Kobarg
    Bristol Myers Squibb Pharmaceutical Research Institute, Seattle, USA
    Eur J Immunol 27:2971-80. 1997
    ....
  9. ncbi Molecular model of the N-terminal receptor-binding domain of the human CD6 ligand ALCAM
    J Bajorath
    Bristol Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121, USA
    Protein Sci 4:1644-7. 1995
    ..Predicted structural characteristics of the A'GFCC'C" face of the model are consistent with the presence of monomeric and dimeric forms of ALCAMD1, which has implications for the receptor-ligand interactions...
  10. ncbi Structure and chromosomal location of the human CD6 gene: detection of five human CD6 isoforms
    M A Bowen
    Bristol Myers Squibb Pharmaceutical Research Institute, Seattle, WA 98121, USA
    J Immunol 158:1149-56. 1997
    ..These transcripts arise via variable splicing of exons encoding the cytoplasmic domain of CD6. The existence of these isoforms suggests that signaling through CD6 could be regulated via alternative splicing of cytoplasmic encoding exons...
  11. ncbi CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase SHP-1
    J J Perez-Villar
    Immunology and Inflammation Drug Discovery, Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543, USA
    Mol Cell Biol 19:2903-12. 1999
    ..These results suggest a critical role of the CD5 ITIM-like motif, which by binding to SHP-1 mediates the down-regulatory activity of this receptor...
  12. ncbi Characterization, mapping and partial cDNA sequence of the 57-kD intracellular Ki-1 antigen
    J Kobarg
    Bristol Myers Squibb, Pharmaceutical Research Institute, Princeton, N J 08543 4000, USA
    Exp Clin Immunogenet 14:273-80. 1997
    ..The Ki-1/57 gene was mapped to the bands 9q22.3-31 of human chromosome 9. This is an area which appears to be associated with secondary chromosomal aberrations in acute myeloid leukemias...
  13. ncbi Identification of a novel inducible cell-surface ligand of CD5 on activated lymphocytes
    L Biancone
    Department of Pathology Harvard Medical School and Pathology Research, Massachusetts General Hospital, Boston 02129, USA
    J Exp Med 184:811-9. 1996
    ..Injection of CD5Rg was found to abrogate development of the disease. Taken together, our results help identify a novel ligand of CD5 and propose a role for CD5 in the regulation of immune responses...
  14. ncbi High circulating levels of soluble scavenger receptors (sCD5 and sCD6) in patients with primary Sjögren's syndrome
    M Ramos-Casals
    Systemic Autoimmune Diseases Unit and. Department of Immunology, , Department of Medicine, , School of Medicine, University of Barcelona, Barcelona, Spain
    Rheumatology (Oxford) 40:1056-9. 2001
    ..These facts may reflect an enhanced lymphocytic activation in patients with primary SS...